Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,648 recruiting studies in this area right now.
By phase
- Not applicable9,813
- Phase 24,456
- Phase 12,744
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer660
- Prostate Cancer656
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer298
- Acute Myeloid Leukemia293
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors195
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University315
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona510
- Florida450
- Alabama420
- New York410
- Massachusetts339
- Maryland330
- New Jersey269
- Pennsylvania240
Recruiting studies20,648 total
- NCT04265937Recruiting
Genetic screening for breast cancer risk in Chinese communities
This study checks certain genes using blood or mouth (oral) samples in people who already have breast cancer. The goal is to better understand genetic risk in Chinese communities and help guide future care.
Shanghai, Shanghai MunicipalityAges Any age - NCT04265872RecruitingEarly Phase 1
Bortezomib then pembrolizumab and cisplatin for metastatic triple-negative breast cancer
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Dallas, TexasAges 18 years+ - NCT04266977Recruiting
Low-dose steroid timing for newly diagnosed brain tumor surgery
This trial looks at using dexamethasone (a steroid medicine) in a more restricted way for people newly diagnosed with likely glioblastoma who are planned for brain surgery. The goal is to see whether limiting steroid use can still control symptoms while reducing steroid exposure.
Sankt Gallen, St.GallenAges 18–90 - NCT04266223Recruiting
Head and neck mask monitoring during radiation to improve setup
This trial tests a surface-monitoring technology that checks a head-and-neck radiation “positioning mask” during treatment. It may help the radiation team make sure the mask and patient are aligned correctly for safer, more accurate therapy.
Blacktown, New South WalesAges 18 years+ - NCT04267978RecruitingPhase 2
Test drug combination for recurrent brain tumor growth
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
BeijingAges 18–70 - NCT04268199RecruitingPhase 2
At-home chemotherapy teaching for people with myeloma
This study tests whether people with symptomatic myeloma can safely learn to give themselves chemotherapy at home. It aims to make treatment easier while tracking safety and whether treatment is done correctly.
Calgary, AlbertaAges 18 years+ - NCT04271527Recruiting
Compare two prostate biopsy guidance methods in men with PSA rise
This trial tests whether using a “cognitive” approach versus a software-guided approach to plan a prostate biopsy is just as effective. It may help improve how biopsies are targeted for men with PSA changes and/or abnormal prostate exams.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT04273061RecruitingPhase 2
Atezolizumab for tumors that look sensitive on DNA/RNA testing
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Vancouver, British ColumbiaAges 18 years+ - NCT04272658Recruiting
Whole-body PET/CT scan during immunotherapy for melanoma
This trial studies how a whole-body PET/CT scan (using a radioactive sugar called FDG) can better track metastatic melanoma in people receiving immune therapy. It may help doctors understand tumor response to medications like nivolumab or pembrolizumab.
Brest, FinistereAges 18 years+ - NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04274283Recruiting
Study of brain tumor samples and blood tests
This trial studies newly diagnosed or progressing brain tumors (grade 2–4 gliomas) to better understand the disease using tumor tissue and blood samples. It may help doctors learn which treatments could work best for different tumor types by matching tumor material to blood results.
BirminghamAges 16 years+ - NCT04275557Recruiting
Using scan and blood data to judge pancreatic cyst risk
This study looks at how medical images and lab samples can predict which pancreatic cysts or tumors are more likely to be dangerous. If you are being evaluated for a pancreatic problem and haven’t started pancreas treatment, your scans and samples may help researchers improve risk prediction.
Lakewood Rch, FloridaAges 18 years+ - NCT04277858RecruitingPhase 2
Pre-surgery chemo plus robotic surgery for p16-positive throat cancer
This trial tests whether giving chemotherapy before robotic surgery works well for certain p16-positive oropharyngeal (throat) cancers. It aims to shrink or control the cancer and allow the surgeon to remove the tumor with clean margins while avoiding cancer spread beyond the neck.
Montreal, QuebecAges 18–80 - NCT04278118Recruiting
Proton radiation study for non-cancer brain tumor types
This trial tests a radiation plan that gives treatment in fewer, larger “fractions” using proton beams (or sometimes photon beams) for certain non-cancer brain tumor types. It aims to see how well this approach works while keeping side effects manageable.
Atlanta, GeorgiaAges 18 years+ - NCT04278222RecruitingPhase 2
Anlotinib plus immunotherapy for advanced stomach cancer
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
ShanghaiAges 18 years+ - NCT04278287RecruitingPhase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
Anyang, HenanAges 18–75 - NCT04280822RecruitingPhase 3
Immunotherapy plus chemo versus chemo alone before surgery
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
Zhengzhou, HenanAges 18–75 - NCT04281381Recruiting
Watching desmoid tumors to understand what changes over time
This study follows people with desmoid-type fibromatosis using scans and health information to see how the tumor behaves. It may help patients and doctors decide when “watch and wait” is the right approach and when treatment is needed.
New York, New YorkAges 18 years+ - NCT04282122Recruiting
Personalized radiation plan for older women with early breast cancer
This trial uses individual measures of how sensitive your body’s tissues are to radiation to guide after-surgery breast radiation treatment. It aims to keep treatment safe and effective while tailoring the plan to each person.
Montpellier, OccAges 65 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04282356RecruitingPhase 2
Test of strong chemotherapy delivered inside the abdomen
This Phase 2 trial tests an intensive treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer. It combines planned surgery to remove visible tumor with chemotherapy that is put directly inside the abdomen during the operation, aiming to control the cancer more effectively.
MontpellierAges 18–75 - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,648 recruiting oncology studies from the U.S. registry right now, out of 31,565 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.